Literature DB >> 10858366

Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas.

C M Bebear1, H Renaudin, A Bryskier, C Bebear.   

Abstract

The activities of telithromycin and levofloxacin against 99 mycoplasma strains were compared to those of several macrolides, ofloxacin, and doxycycline. Telithromycin MICs of </=0.25 microgram/ml were found for all isolates, except for Mycoplasma hominis, while levofloxacin was active at concentrations of </=1 microgram/ml against all species studied.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10858366      PMCID： PMC89997          DOI： 10.1128/AAC.44.7.1980-1982.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

2.  In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas.

Authors:  C M Bébéar; H Renaudin; A Boudjadja; C Bébéar
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

3.  In-vitro activity of ketolides against mycoplasmas.

Authors:  C M Bébéar; H Renaudin; M D Aydin; J F Chantot; C Bébéar
Journal:  J Antimicrob Chemother       Date:  1997-05       Impact factor: 5.790

4.  The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp.

Authors:  G L Ridgway; H Salman; M J Robbins; C Dencer; D Felmingham
Journal:  J Antimicrob Chemother       Date:  1997-12       Impact factor: 5.790

5.  In vitro susceptibilities of Mycoplasma hominis to six fluoroquinolones as determined by E test.

Authors:  K B Waites; K C Canupp; G E Kenny
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 6.  New quinolones and gram-positive bacteria.

Authors:  L J Piddock
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

7.  In vitro activities of two ketolides, HMR 3647 and HMR 3004, against gram-positive bacteria.

Authors:  K Malathum; T M Coque; K V Singh; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

8.  Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis.

Authors:  C M Bebear; J Renaudin; A Charron; H Renaudin; B de Barbeyrac; T Schaeverbeke; C Bebear
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

Review 9.  Antibiotic susceptibilities of mycoplasmas and treatment of mycoplasmal infections.

Authors:  D Taylor-Robinson; C Bébéar
Journal:  J Antimicrob Chemother       Date:  1997-11       Impact factor: 5.790

10.  Tetracycline-resistant Mycoplasma hominis strains contain streptococcal tetM sequences.

Authors:  M C Roberts; L A Koutsky; K K Holmes; D J LeBlanc; G E Kenny
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191
View more
  17 in total

1.  Antibiotic susceptibility testing of Mycoplasma genitalium by TaqMan 5' nuclease real-time PCR.

Authors:  Ryoichi Hamasuna; Yukio Osada; Jørgen Skov Jensen
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 2.  Community-acquired pneumonia related to intracellular pathogens.

Authors:  Catia Cillóniz; Antoni Torres; Michael Niederman; Menno van der Eerden; James Chalmers; Tobias Welte; Francesco Blasi
Journal:  Intensive Care Med       Date:  2016-06-08       Impact factor: 17.440

3.  Telithromycin.

Authors:  J A Balfour; D P Figgitt
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Mycoplasma genitalium: should we treat and how?

Authors:  Lisa E Manhart; Jennifer M Broad; Matthew R Golden
Journal:  Clin Infect Dis       Date:  2011-12       Impact factor: 9.079

Review 5.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 6.  Telithromycin.

Authors:  Keri Wellington; Stuart Noble
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  The ketolides: a critical review.

Authors:  George G Zhanel; Michael Walters; Ayman Noreddin; Lavern M Vercaigne; Aleksandra Wierzbowski; John M Embil; Alfred S Gin; Stephen Douthwaite; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

9.  In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Xue Bing; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

10.  In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.

Authors:  Ken B Waites; Donna M Crabb; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.